Cirujana Mastóloga Hospital Británico de Buenos Aires.
Joined January 2014
- Tweets1.4K
- Following1.2K
- Followers293
- Likes13.5K
Gabriela Candás retweeted
Al final, el que decide cuándo es feriado es el Chiqui Tapia? Entendí bien?
Gabriela Candás retweeted
Hay libros que se leen. Y hay libros que te acompañan para siempre.
Para mí, La sombra del viento, de Carlos Ruiz Zafón, es una de las mejores novelas de la historia. Estas son algunas de las frases que habitan entre sus páginas y que más me han marcado. 🧵⁸
Gabriela Candás retweeted
La AAOC felicita al Dr. @DiegoEnricoMD por haber obtenido el International Innovation Grant de @ConquerCancerFd @ASCO, por el que realizará un estudio académico para evaluar la aplicación móvil ePROtector, potenciada por #IA, para el monitoreo y manejo de efectos adversos
Gabriela Candás retweeted
#elizanetant improves not only vasomotor symptoms but also sleep for patients on all types (tamoxifen, AI, and GNRH ) endocrine therapy for #bcsm
#ASCO26
Gabriela Candás retweeted
In a patient-informed trial design, pre pectoral implants shown to
Improve chest well being with a slightly higher rate of loss of implant/ expander than sub pectoral #ASCO26 @OncoAlert
Gabriela Candás retweeted
#ASCO26
SENOMAC: Completion ALND can be omitted in clinically node-negative breast cancer patients with 1–2 sentinel lymph node macrometastases!!
#ASCO26
In SENOMAC, omission of completion ALND appears oncologically safe in patients with cN0 T1–3 breast cancer and 1–2 sentinel node macrometastases.
Median follow-up: 60 months
5-year OS: 93.4% vs 94.4%
5-year BCSS: 97.3% vs 97.8%
Arm morbidity was significantly higher with ALND.
The study population was largely low axillary burden and luminal disease: ER+/HER2− 86.6%, T3 tumors 5.8%, mastectomy 36.2%, and a single SLN macrometastasis in 84.7% of patients. Regional nodal irradiation was delivered in ~89%.
In this context, routine completion ALND after a positive SLN is becoming increasingly difficult to justify.
Gabriela Candás retweeted
In a patient-informed trial design, Pre pectoral implant design is shown to improve primary endpoint of “chest well being” with slightly higher rate of unplanned implant/expander loss than sub pectoral #ASCO26 @OncoAlert
Gabriela Candás retweeted
My favorite study so far: PHERGain-2.
High pCR rates with chemo-free neoadjuvant HP in selected small node-negative HER2 IHC 3+ disease.
Now the big questions:
1: will EFS hold up long term?
2: how many cycles of T-DM1 are really needed after RD? #ESMOBreast #bcsm
Gabriela Candás retweeted
Ongoing PI3Ki studies with many promising agents coming through the pipeline. #ESMOBreast26
Gabriela Candás retweeted
Cancer survival just crossed 70% in the U.S.
It was 63% in the 90s.
That gap = 4.8M people alive today.
Myeloma: 32% → 62%
Melanoma (metastatic): 16% → 35%
Lung (metastatic): 2% → 10%
That is not abstract progress.
These are birthdays, grandkids,
& years of memories restored.
Sure, we have ways to go.
But this is what funded science does.
Next time someone asks if cancer research works,
show them this chart.
- - - - -
Source: ACS Cancer Stats. 2026 + SEER (via @Jori_health)
- - - - -
Gabriela Candás retweeted
📌 Tailored Exercise Strategies and Mortality Among Breast Cancer Survivors
🔗 jamanetwork.com/journals/jam…
@OncoAlert #OncoAlertAF @ijergas @JacBVo @JAMANetworkOpen
👉🏻 In this cohort study using a target trial emulation design, tailored exercise strategies were associated with reductions in 10-year mortality among breast cancer survivors. A randomized trial is warranted to confirm these findings. 🩺🏃🏻♀️
Gabriela Candás retweeted
Very odd and contradictory to see this post and the new @ACP breast cancer screening guideline post simultaneously in one night. So much work to be done still. Sigh. @NCCN #breastcancer
💻 #ASCOAI: #AI accepted in screening guidelines
@NCCN now recommends earlier #breastcancer screening (age 35) for high-risk women identified by AI or risk assessment tools.
‼️ A significant move toward personalized screening.
Read more here ➡️ ascoai.org/articles/2026/04/…
Gabriela Candás retweeted
Big News for AI and Breast Cancer Screening.
For decades, these women walked out of their mammogram labeled “average risk” and sent home.
NCCN’s 2026 guidelines just changed the calculus. AI analysis of a routine mammogram can now identify women with a ≥1.7% five-year breast cancer risk starting at age 35, including the majority who would never have been flagged by genetics or family history alone.
What happens when you’re identified? This isn’t just a number.
The guidelines link that risk score directly to action:
•Supplemental imaging (MRI, ultrasound)
•Consideration of risk-reduction strategies (chemoprevention, lifestyle)
•Periodic reassessment, because risk changes over time
This means a woman who would have been told “see you next year” may instead get an MRI that finds a 6mm cancer. Or start a conversation about tamoxifen.
The mammogram was always carrying this information. AI can now read it. And NCCN is saying: act on it. #onclive #bcsm #oncoalert
The @NCCN has updated its 2026 Clinical Practice Guidelines in oncology for breast cancer screening and diagnosis to include Clairity Breast, an AI-based risk assessment tool that analyzes mammograms and assesses patients’ future risk for breast cancer development #bcsm #oncology
Read more: onclive.com/view/clairity-br…
Gabriela Candás retweeted
🔬 The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic #BreastCancer by measuring HER2 levels and DNA instability. targetedonc.com/view/genomic…
Gabriela Candás retweeted
New JAMA Surgery guidelines from ASBrS, SBI & CAP clarify management of infectious & inflammatory breast conditions, improving consistency in patient care.
Full article: jamanetwork.com/journals/jam…
Gabriela Candás retweeted
This week is Adolescent & Young Adult Cancer Awareness Week.
This week focuses on ~89,000 people 15–39 diagnosed w/ cancer annually. This week highlights the unique challenges faced: lower survival improvements, fertility, financial stress, & disruption to education & careers!
Gabriela Candás retweeted
🎀HER2-positive breast cancer is no longer what it used to be.
oncodaily.com/oncolibrary/he…
What was once one of the most aggressive subtypes has become one of the most precisely targeted and treatable diseases in oncology.
From the landmark CLEOPATRA trial showing a 56.5-month overall survival, to the breakthrough of trastuzumab deruxtecan (T-DXd) with a 72% reduction in progression risk (HR 0.28) in DESTINY-Breast03, the field has rapidly evolved.
And it doesn’t stop there.
The HER2CLIMB trial changed outcomes for patients with brain metastases, while DESTINY-Breast06 expanded HER2 targeting beyond traditional definitions.
Today, treatment is no longer about a single drug, it’s about strategic sequencing, precision, and timing.
👉 First-line still relies on dual HER2 blockade
👉 Second-line is now dominated by ADCs
👉 CNS-active therapies are reshaping outcomes
The big question now:
Can next-generation strategies redefine first-line therapy?
@GiuseppeBuono88 @stolaney1 @PTarantinoMD
#BreastCancer #HER2 #Oncology #ClinicalTrials #TargetedTherapy #PrecisionMedicine #OncoDaily #OncoDailyBreast
Gabriela Candás retweeted
@Neil_Iyengar presents a small fascinating plant based diet intervention in pts with MBC with 17% weight loss comparable to GLP1 agonists. Fascinating talk including an exercise intervention in MBC #MBCC26 @OncoAlert
Gabriela Candás retweeted
In TNBC, adding weekly carboplatin to neoadjuvant therapy increases OS by an absolute 7.6% in premenopausal patients ‼️
@TataMemorial✨️✨️
Thrilled to share our phase III randomized controlled trial thst demonstrates improved survival by adding platinum based chemotherapy to treat patients with triple negative breast cancer. A step forward in a challenging disease! #BreastCancer #TNBC ascopubs.org/doi/10.1200/JCO…
